Twist Bioscience Expects Q1 FY24 Revenue Of $67M-$68M Vs. Consensus Of $62.98M, With Gross Margin Of Around 38%-39%
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience anticipates Q1 FY24 revenue to be between $67M-$68M, surpassing the consensus estimate of $62.98M. The company also projects a gross margin of approximately 38%-39% for the same period.
November 17, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience expects higher-than-anticipated Q1 FY24 revenue of $67M-$68M, beating the consensus of $62.98M, and estimates a gross margin of 38%-39%.
The positive revenue forecast by Twist Bioscience is likely to instill confidence in investors, potentially leading to a short-term increase in the stock price. The expected revenue surpasses analyst consensus, which is a bullish signal. The projected gross margin also suggests operational efficiency, further supporting the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100